Buffalo and then after relocation to Albany, began the difficult search for the identity of a plasma membrane thyroid hormone receptor. In 1980, Sterling, Brenner, and Sakurada (10) reported further evidence for rapid cellular actions of thyroid hormones, in this case stimulation of mitochondrial function in the absence of de novo protein production, and the following year the Davis group published their first paper (3), titled "In vitro stimulation of human red blood cell Ca ϩ2 -ATPase by thyroid hormone," clearly establishing a nongenomic action.
cancers. Actions of tetrac unrelated to thyroid hormones have been demonstrated as well, in particular its ability to antagonize the angiogenic actions of vascular endothelial growth factor (VEGF) and bovine fibroblast growth factor (bFGF). By itself, without interacting with endogenous growth factors, tetrac activates proapoptotic genes, and its potential use in the treatment of several cancers can now be envisioned (6) .
Exciting new findings include the observation (7) that tetrac sensitized cultured cancer cells to subsequent radiation exposure (i.e., radiosensitization) and that in human breast cancer cells tetrac treatment prolonged the residence time of doxorubicin (8), suggesting a potential mechanism by which the efficacy of chemotherapeutic agents can be enhanced. This is an outstanding story of discovery and dedication. It demonstrates the importance of clinical observations that can be examined experimentally in animal models and the important boost that research received as we progressed into the molecular era. Just as significant is the demonstration in this story of the translational aspect of endocrine research and how quickly discoveries at the bench can progress to potential treatments for devastating diseases. The work of Pepper and Faith Davis serves as an inspiration and a lesson to all researchers and particularly to young scientists. Keep your eyes open and be flexible; an unexpected answer is often right in front of you.
